[{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Mazindol","moa":"MAO transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Adare Pharma Solutions \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"TPG Capital IP","sponsor":"Ellodi Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"TPG Capital IP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TPG Capital IP \/ TPG Capital IP","highestDevelopmentStatusID":"10","companyTruncated":"TPG Capital IP \/ TPG Capital IP"},{"orgOrder":0,"company":"Adare Pharma Solutions","sponsor":"Laxxon Medical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Adare Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Adare Pharma Solutions \/ Laxxon Medical","highestDevelopmentStatusID":"12","companyTruncated":"Adare Pharma Solutions \/ Laxxon Medical"}]

Find Clinical Drug Pipeline Developments & Deals by Adare Pharma Solutions

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The partnership aims to leverage Adare's state-of-the-art cGMP facilities and Laxxon's innovative 3D printing technology to bring innovative new oral dosage forms to market.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 18, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Laxxon Medical

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Ellodi Pharmaceuticals is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare).

                          Brand Name : APT-1011

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 22, 2020

                          Lead Product(s) : Fluticasone Propionate

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase III

                          Recipient : Ellodi Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 13, 2020

                          Lead Product(s) : Mazindol

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase II

                          Sponsor : NLS Pharmaceutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank